多发性骨髓瘤的临床前动物模型。
Preclinical animal models of multiple myeloma.
作者信息
Lwin Seint T, Edwards Claire M, Silbermann Rebecca
机构信息
Nuffield Department of Surgical Sciences, University of Oxford , Oxford, UK.
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK.
出版信息
Bonekey Rep. 2016 Feb 3;5:772. doi: 10.1038/bonekey.2015.142. eCollection 2016.
Abstract
Multiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and immunosuppression. Murine models of multiple myeloma and myeloma bone disease are critical tools for an improved understanding of the pathogenesis of the disease and the development of novel therapeutic strategies. This review will cover commonly used immunocompetent and xenograft models of myeloma, describing the advantages and disadvantages of each model system. In addition, this review provides detailed protocols for establishing systemic and local models of myeloma using both murine and human myeloma cell lines.
摘要
多发性骨髓瘤是一种无法治愈的浆细胞恶性肿瘤，其特征为溶骨性骨病和免疫抑制。多发性骨髓瘤和骨髓瘤骨病的小鼠模型是增进对该疾病发病机制的理解以及开发新型治疗策略的关键工具。本综述将涵盖常用的骨髓瘤免疫活性模型和异种移植模型，描述每个模型系统的优缺点。此外，本综述还提供了使用小鼠和人类骨髓瘤细胞系建立骨髓瘤全身和局部模型的详细方案。
相似文献
1
Preclinical animal models of multiple myeloma.多发性骨髓瘤的临床前动物模型。
Bonekey Rep. 2016 Feb 3;5:772. doi: 10.1038/bonekey.2015.142. eCollection 2016.
2
A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.对目前用于评估治疗药物对肿瘤生长和骨病疗效的多发性骨髓瘤小鼠模型的综述。
Bone. 2015 Aug;77:57-68. doi: 10.1016/j.bone.2015.04.004. Epub 2015 Apr 11.
3
Animal Models of Multiple Myeloma Bone Disease.多发性骨髓瘤骨病的动物模型
Front Genet. 2021 Jun 7;12:640954. doi: 10.3389/fgene.2021.640954. eCollection 2021.
4
[Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].[表达脑源性神经营养因子的多发性骨髓瘤小鼠模型的建立]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):967-72.
5
Differential Pain-Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma.骨髓瘤免疫活性小鼠模型中与疼痛相关的差异行为和骨病
JBMR Plus. 2019 Dec 30;4(2):e10252. doi: 10.1002/jbm4.10252. eCollection 2020 Feb.
6
Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.抑制p38α丝裂原活化蛋白激酶可预防溶骨性骨病的发展，减轻肿瘤负担，并提高多发性骨髓瘤小鼠模型的生存率。
Cancer Res. 2007 May 15;67(10):4572-7. doi: 10.1158/0008-5472.CAN-06-4361. Epub 2007 May 10.
7
Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.细胞粘附分子CD166驱动多发性骨髓瘤的恶性进展和溶骨性疾病。
Cancer Res. 2016 Dec 1;76(23):6901-6910. doi: 10.1158/0008-5472.CAN-16-0517. Epub 2016 Sep 7.
8
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.骨骼与多发性骨髓瘤之间的动态相互作用：成骨细胞的新作用
Bone. 2015 Jun;75:161-9. doi: 10.1016/j.bone.2015.02.021. Epub 2015 Feb 26.
9
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.抑制Dickkopf-1（Dkk1）可消除对骨形成的抑制，并预防多发性骨髓瘤中溶骨性骨病的发展。
J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.
10
The use of animal models in multiple myeloma.动物模型在多发性骨髓瘤中的应用。
Morphologie. 2015 Jun;99(325):63-72. doi: 10.1016/j.morpho.2015.01.003. Epub 2015 Apr 17.
引用本文的文献
1
In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [C]HSP990 in Healthy Aging and Neurodegeneration.利用[C]HSP990对健康衰老和神经退行性变过程中脑热休克蛋白90进行体内可视化和定量分析。
J Nucl Med. 2025 Jun 2;66(6):940-947. doi: 10.2967/jnumed.124.268961.
2
Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.γ干扰素介导的多发性骨髓瘤小鼠模型中肿瘤进展的预防
Hemasphere. 2024 Dec 2;8(12):e70047. doi: 10.1002/hem3.70047. eCollection 2024 Dec.
3
Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.磁共振成像（MRI）上脾脏T2信号强度降低与多发性骨髓瘤的疾病负担相关。
Eur Radiol. 2025 Jun;35(6):3576-3586. doi: 10.1007/s00330-024-11191-8. Epub 2024 Nov 27.
4
Orthotopic and metastatic tumour models in preclinical cancer research.临床前癌症研究中的原位和转移瘤模型。
Pharmacol Ther. 2024 May;257:108631. doi: 10.1016/j.pharmthera.2024.108631. Epub 2024 Mar 11.
5
HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM.HAPLN1 基质素：一种与 MM 患者不良预后相关的骨髓归巢因子。
Blood Adv. 2023 Nov 28;7(22):6859-6872. doi: 10.1182/bloodadvances.2023010139.
6
Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles.使用针对 CD38 的脂质纳米颗粒将治疗性 RNA 递送至多发性骨髓瘤的骨髓中。
Adv Sci (Weinh). 2023 Jul;10(21):e2301377. doi: 10.1002/advs.202301377. Epub 2023 May 12.
7
Obesity and myeloma: Clinical and mechanistic contributions to disease progression.肥胖与骨髓瘤：疾病进展的临床和机制贡献。
Front Endocrinol (Lausanne). 2023 Feb 23;14:1118691. doi: 10.3389/fendo.2023.1118691. eCollection 2023.
8
Radiosynthesis and preclinical evaluation of [C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging.[C]SNX-ab作为一种用于体内脑和肿瘤成像的Hsp90α、β亚型选择性PET探针的放射性合成及临床前评估。
EJNMMI Radiopharm Chem. 2023 Jan 30;8(1):2. doi: 10.1186/s41181-023-00189-0.
9
Animal Models of Multiple Myeloma Bone Disease.多发性骨髓瘤骨病的动物模型
Front Genet. 2021 Jun 7;12:640954. doi: 10.3389/fgene.2021.640954. eCollection 2021.
10
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.实验室小鼠——人类多发性骨髓瘤免疫病理学和免疫治疗研究的推动力量。
Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021.
本文引用的文献
1
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.多发性骨髓瘤的免疫监视与治疗依赖于CD226。
J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15.
2
A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.对目前用于评估治疗药物对肿瘤生长和骨病疗效的多发性骨髓瘤小鼠模型的综述。
Bone. 2015 Aug;77:57-68. doi: 10.1016/j.bone.2015.04.004. Epub 2015 Apr 11.
3
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.NOD/SCID-γ小鼠是评估用于治疗骨髓瘤骨病的治疗药物疗效的理想品系。
PLoS One. 2015 Mar 13;10(3):e0119546. doi: 10.1371/journal.pone.0119546. eCollection 2015.
4
GP130 activation induces myeloma and collaborates with MYC.GP130激活可诱导骨髓瘤并与MYC协同作用。
J Clin Invest. 2014 Dec;124(12):5263-74. doi: 10.1172/JCI69094. Epub 2014 Nov 10.
5
Diet-induced obesity promotes a myeloma-like condition in vivo.饮食诱导的肥胖在体内促进类似骨髓瘤的病症。
Leukemia. 2015 Feb;29(2):507-10. doi: 10.1038/leu.2014.295. Epub 2014 Oct 7.
6
SAMSN1 is a tumor suppressor gene in multiple myeloma.SAMSN1是多发性骨髓瘤中的一种肿瘤抑制基因。
Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002.
7
Engineered nanomedicine for myeloma and bone microenvironment targeting.用于骨髓瘤和骨微环境靶向的工程纳米医学。
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92. doi: 10.1073/pnas.1401337111. Epub 2014 Jun 30.
8
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.（18）F-FDG-PET/CT 成像在人多发性骨髓瘤的 IL-6 和 MYC 驱动的小鼠模型中，可客观评估浆细胞瘤肿瘤的进展和对蛋白酶体抑制剂伊沙佐米的治疗反应。
Blood Cancer J. 2013 Nov 29;3(11):e165. doi: 10.1038/bcj.2013.61.
9
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.采用同源 Vk*MYC 多发性骨髓瘤进行组蛋白去乙酰化酶抑制剂联合 ABT-737、rhTRAIL/MD5-1 或 5-氮杂胞苷的临床前筛选。
Cell Death Dis. 2013 Sep 12;4(9):e798. doi: 10.1038/cddis.2013.306.
10
Mechanisms of multiple myeloma bone disease.多发性骨髓瘤骨病的发病机制。
Bonekey Rep. 2012 Aug 1;1:135. doi: 10.1038/bonekey.2012.135. eCollection 2012.
Zotero 插件